Evidence map›Paper›PMID 34466142›Full record

ReviewExperimental and therapeutic medicine2021

Tumor microenvironment is not an 'innocent bystander' in the resistance to treatment of head and neck cancers (Review).

Laura Mazilu, Andra-Iulia Suceveanu, Dana-Lucia Stanculeanu, Andreea-Daniela Gheorghe, Gabriela Fricatel, Serban-Mircea Negru

Abstract readReview
In one paragraph

Review in Experimental and therapeutic medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Laura MaziluDepartment of Oncology, 'Ovidius' University, 900527 Constanţa, Romania.
Andra-Iulia SuceveanuDepartment of Gastroenterology, 'Ovidius' University, 900527 Constanţa, Romania.
Dana-Lucia StanculeanuDepartment of Oncology, 'Carol Davila' University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Andreea-Daniela GheorgheDepartment of Oncology, 'Ovidius' University, 900527 Constanţa, Romania.
Gabriela FricatelDepartment of Oncology, 'Ovidius' University, 900527 Constanţa, Romania.
Serban-Mircea NegruDepartment of Oncology, 'Victor Babes' University of Medicine and Pharmacy, 300041 Timisoara, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Head and neck cancers are still one of the most common types of cancer in the world. They rank in the leading sixth place in terms of incidence globally, and the incidence continues to rise. The mortality rates remain at high levels. Pathological subclassification places squamous cell carcinoma of the head and neck (HNSCC) in the first place concerning the histological forms of head and neck cancers; a tumor with extremely aggressive behavior and high mortality rates. The tumor microenvironment is a very complex ecosystem of cellular and non-cellular components, characterized by unique features, that contribute to the appearance of immunosuppression and diminished anticancer immunity, impacting patient prognosis and treatment outcome. Despite many important advances in therapy, resistance to therapy represents a difficult challenge in HNSCC patients. Tumor progression, metastasis, and response to therapy are all influenced by the complex ecosystem represented by the tumor microenvironment and by the interactions between cellular and non-cellular components of this system. Therefore, the tumor microenvironment, in the light of recent data, is not an innocent bystander. In the last few years, there has been a sustained effort to characterize the tumor microenvironment, to identify targets of response and identify other mechanisms of tumor-specific immune responses, or to discover other biomarkers of response. There is an urgent need to understand how to properly select patients, the therapy sequence, and how to use feasible biomarkers that can help to identify the patient who may obtain the most benefit from available therapies.

Indexed as

biomarkers of responsehead and neck cancersmicrobiotamicrosatellite instabilitysquamous cell carcinomatumor microenvironment

Identifiers

PMID34466142
PMCPMC8383332

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.